Clinical effect of irbesartan combined with Qiliqiangxin capsule on ischemic cardiomyopathy complicated with chronic heart failure

Lyu Jungang; Pang Aibo; Zhai Li; Cao Tiantian; Wang Songtao; Wang Zhenguo; Zhao Lin

doi:10.3760/j.issn.1673-4777.2020.01.003

Abstract：Objective To investigate the clinical effect of irbesartan combined with Qiliqiangxin capsule on ischemic cardiomyopathy with chronic heart failure.Methods Totally 88 patients with ischemic cardiomyopathy and chronic heart failure admitted to Beijing General Hospital of the Chinese People's Armed Police Force from August 2017 to February 2019 were randomly divided into control group(44 cases) and observation group(44 cases).On the basis of routine treatment,the control group took irbesartan while the observation group took irbesartan plus Qiliqiangxin capsule.Both groups were treated for 1 month.Clinical efficacy,left ventricular ejection fraction (LVEF),left ventricular end-diastolic diameter(LVEDD),serum B-type natriuretic peptide (BNP) and cardiac troponin I(cTnI) levels,6 min walking distance and adverse reactions were analyzed.Results The total effective rate in observation group was significantly higher/longer than that in control group [90.9％ (40/44) vs 75.0％ (33/44)] (P ＜ 0.05).There were no significant differences in LVEDD,LVEF,BNP,cTnI and 6 min walking distance between groups before treatment(all P ＞ 0.05).After treatment,LVEDD,LVEF,BNP,cTnI and 6 min walking distance were improved in both groups;LVEDD,BNP and cTnI in observation group were significantly lower than those in control group [(48.7 ± 2.4) mm vs (52.6 ± 2.6) mm,(366 ± 23) ng/L vs (596 ± 21) ng/L,(0.30 ± 0.10) μg/L vs (0.35 ± 0.07) μg/L];LVEF and 6 min walking distance in observation group were significantly higher/longer than those in control group [(43.2 ± 4.6) ％ vs (36.5 ± 5.4) ％,(422 ± 10) m vs (379 ± 12)m] (all P ＜ 0.05).The incidence of adverse reactions in observation group was lower than that in control group,but the difference was not statistically significant (P ＞ 0.05).Conclusion Irbesartan combined with Qiliqiangxin capsule treating ischemic cardiomyopathy with chronic heart failure can effectively improve cardiac function without increasing the incidence of adverse reactions.